Aspira Women's Health, Inc. (AWH)
| Market Cap | 47.23M |
| Revenue (ttm) | 7.48M |
| Net Income (ttm) | -36.18M |
| Shares Out | 116.62M |
| EPS (ttm) | -0.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 564,769 |
| Open | 0.391 |
| Previous Close | 0.380 |
| Day's Range | 0.370 - 0.410 |
| 52-Week Range | 0.320 - 3.510 |
| Beta | 2.87 |
| Analysts | Buy |
| Price Target | 3.06 (+655.6%) |
| Earnings Date | Nov 8, 2022 |
About AWH
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates AS... [Read more...]
Financial Performance
In 2021, AWH's revenue was $6.81 million, an increase of 46.46% compared to the previous year's $4.65 million. Losses were -$31.66 million, 76.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for AWH stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 655.56% from the latest price.
News
Here's Why Aspira (AWH) Looks Ripe for Bottom Fishing
Aspira (AWH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Stree...
Aspira Women's Health Announces Publication of its Second-Generation MultiVariate Index Assay, OVERA®, in the Detecti...
Data demonstrates the accuracy of Aspira's multivariate assessment test OVERA in a non-White population and concludes use of OVERA to be better than CA-125 in detecting early-stage cancer in women with ...
Down 38.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Aspira (AWH)
The heavy selling pressure might have exhausted for Aspira (AWH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in rev...
Aspira Women's Health Inc. Announces Proposed Public Offering
AUSTIN, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women's health company focused on gynecologic disease, today announced it has...
Aspira Women's Health Hosting Women's Health Webinar on Ovarian Cancer Risk Assessments Utilizing Multivariant Index ...
KOL Event to take place on Wednesday, August 24th at 12:00pm ET KOL Event to take place on Wednesday, August 24th at 12:00pm ET
Aspira Women's Health Reports Second Quarter 2022 Financial Results
Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units
Aspira Women's Health to Announce Second Quarter 2022 Financial Results and Host Conference Call on Wednesday, August 10
AUSTIN, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”), a bio-analytical based women's health company focused on gynecologic disease, today announced that the company wil...
Aspira Women's Health Announces Appointment of Two New Board Members
Seasoned Directors further strengthen Board with decades of industry and leadership experience Seasoned Directors further strengthen Board with decades of industry and leadership experience
Aspira Women's Health Announces Publication of Paper Validating OvaWatch™ Algorithm in the Detection of Ovarian Cancer
Paper published in the June online issue of JCO Clinical Cancer Informatics Paper published in the June online issue of JCO Clinical Cancer Informatics
Aspira Women's Health to Participate in the Upcoming Investor Conferences
AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that management will participate in the “MicroCap ...
Aspira (AWH) Reports Q1 Loss, Misses Revenue Estimates
Aspira (AWH) delivered earnings and revenue surprises of 0% and 5.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aspira Women's Health Reports First Quarter 2022 Financial Results
Product Revenue Increased 30% to $1.8 million; OVA1plus Volume Grew 28% to 4,819 Units
Aspira Women's Health to Announce First Quarter 2022 Financial Results and Host Conference Call on Wednesday, May 11
AUSTIN, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that the company will report its financial resu...
Aspira (AWH) Reports Q4 Loss, Lags Revenue Estimates
Aspira (AWH) delivered earnings and revenue surprises of 11.11% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Aspira Women's Health Reports Fourth Quarter and Full Year 2021 Financial Results
Total Revenue Increased 46% to $6.8 million; OVA1 Volume Grew 28% to 17,359 Units
Aspira Women's Health to Announce Year End 2021 Financial Results and Host Conference Call on Wednesday, March 23
AUSTIN, Texas, March 15, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that the company will report its financial resu...
Aspira Women's Health Announces Appointment of Celeste Fralick, Ph.D., to its Board of Directors
AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced the appointment of Celeste Fralick, Ph.D., to its...
Valerie Palmieri Elevated to Executive Chair of the Board; Nicole Sandford Appointed President and CEO
Expanded leadership team to drive strategic partnerships, accelerate new commercial launches, and grow overall enterprise value Expanded leadership team to drive strategic partnerships, accelerate new c...
Aspira Women's Health, Inc. Expands Senior Leadership Team with Addition of Mr. Michael Newton as Head of Sales and M...
AUSTIN, Texas, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced the appointment of Mr. Michael Newton as Head of...
Aspira Women's Health to Participate in the Upcoming Winter Wonderland Best Ideas Conference
AUSTIN, Texas, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that management will participate in the 2nd Annu...
Aspira Women's Health Announces the Addition of 465,000 Covered Lives Through Medicaid Credentialing
AUSTIN, Texas, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, announced today that it has entered into agreements to provide i...
Aspira (AWH) Reports Q3 Loss, Tops Revenue Estimates
Aspira (AWH) delivered earnings and revenue surprises of -12.50% and 11.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aspira Women's Health Reports Third Quarter 2021 Financial Results
Total Revenue Increased 34% to $1.67 million; OVA1 Volume Grew 19% to 4,281 Units
Earnings Preview: Aspira (AWH) Q3 Earnings Expected to Decline
Aspira (AWH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aspira Women's Health Executes Four Aspira SynergyTM Technology Transfer Agreements
Aspira Women's Health has entered into partnership agreements with two of the largest U.S.-based women's health networks and two independent U.S. laboratories. Aspira Women's Health has entered into par...